Last reviewed · How we verify
Decreased respiratory function — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Dopram | DOXAPRAM | Hikma | Respiratory Stimulant | Cytochrome P450 2D6 | 1965-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Hikma · 1 drug in Decreased respiratory function
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Decreased respiratory function:
- Decreased respiratory function treatment updates — RSS
- Decreased respiratory function treatment updates — Atom
- Decreased respiratory function treatment updates — JSON
Cite this brief
Drug Landscape (2026). Decreased respiratory function — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/decreased-respiratory-function. Accessed 2026-06-10.
Related
- Decreased respiratory function full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing